Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Grace Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 12 | 15 | +3 |
| Shares | 2.12M | 2.09M | −31.7K (−1.5%) |
| Value | $6.36M | $7.84M | +$1.47M (+23.2%) |
New holders (4)
Institutions that held Grace Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 225,000 | $857.3K | 0.00% |
| Citadel Advisors LLC | 23,664 | $90.2K | 0.00% |
| Golden State Wealth Management, LLC | 31 | $116 | 0.00% |
| SBI Securities Co., Ltd. | 1 | $4 | 0.00% |
Sold out (1)
Institutions that held Grace Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| UBS Group AG | 28 | $84 |